Javascript must be enabled to continue!
Thymoquinone, but Not Metformin, Protects against Gentamicin-Induced Nephrotoxicity and Renal Dysfunction in Rats
View through CrossRef
Background: Gentamicin (GM) is an antibiotic that is widely used to treat many Gram-negative bacteria, such as those involved in urinary tract infections. However, being nephrotoxic, GM dose adjustment and reno-protective elements must be concurrently administered with GM to minimize kidney damage. Oxidative stress plays a pivotal role in the pathogenesis of GM-induced nephrotoxicity. Thymoquinone (TQ) is a promising therapeutic substance, that is being extensively studied in many diseases, such as diabetes mellitus, cancer, hypertension, and others. The powerful antioxidant properties of TQ may greatly help in minimizing GM nephrotoxicity. Metformin (MF) is a well-known, clinically approved oral hypoglycaemic drug that has many other actions, including antioxidant properties. The aim of this work was to evaluate the possible antioxidant and reno-protective effects of TQ and metformin in GM-induced nephrotoxicity in the same model (rats) at the same time. In addition, we aimed to further understand the effects underlying GM-induced nephrotoxicity. Methods: Twenty male rats were randomly divided into four equal groups: the first group (control) received distilled water; the second group received GM only; the third group received concurrent oral TQ and GM; and the fourth group received concurrent oral MF and GM. After 4 weeks, renal function and histopathology, as well as levels of the oxidative markers glutathione peroxidase-1 (GLPX1), superoxide dismutase (SOD), and malondialdehyde (MDA) in the kidney tissues, were assessed. Results: Compared with the control group, and as expected, the GM-injected rats showed significant biochemical and histological changes denoting renal damage. Compared with GM-injected rats, the concurrent administration of TQ with GM significantly reduced the levels of serum creatinine, serum urea, and tissue MDA and significantly increased the levels of GLPX1 and SOD. Concurrent metformin administration with GM significantly increased the levels of both GLPX1 and SOD and significantly decreased the levels of tissue MDA but had no significant effect on serum creatinine and urea levels. Compared with GM-injected rats, the addition of either TQ or MF resulted in a reduction in endothelial proliferation and mesangial hypercellularity. Conclusions: Both TQ and MF effectively alleviated the oxidative stress in GM-induced nephrotoxicity in rats, with TQ but not MF producing a complete reno-protective effect. Further studies for evaluation of different reno-protective mechanisms of TQ should be conducted.
Title: Thymoquinone, but Not Metformin, Protects against Gentamicin-Induced Nephrotoxicity and Renal Dysfunction in Rats
Description:
Background: Gentamicin (GM) is an antibiotic that is widely used to treat many Gram-negative bacteria, such as those involved in urinary tract infections.
However, being nephrotoxic, GM dose adjustment and reno-protective elements must be concurrently administered with GM to minimize kidney damage.
Oxidative stress plays a pivotal role in the pathogenesis of GM-induced nephrotoxicity.
Thymoquinone (TQ) is a promising therapeutic substance, that is being extensively studied in many diseases, such as diabetes mellitus, cancer, hypertension, and others.
The powerful antioxidant properties of TQ may greatly help in minimizing GM nephrotoxicity.
Metformin (MF) is a well-known, clinically approved oral hypoglycaemic drug that has many other actions, including antioxidant properties.
The aim of this work was to evaluate the possible antioxidant and reno-protective effects of TQ and metformin in GM-induced nephrotoxicity in the same model (rats) at the same time.
In addition, we aimed to further understand the effects underlying GM-induced nephrotoxicity.
Methods: Twenty male rats were randomly divided into four equal groups: the first group (control) received distilled water; the second group received GM only; the third group received concurrent oral TQ and GM; and the fourth group received concurrent oral MF and GM.
After 4 weeks, renal function and histopathology, as well as levels of the oxidative markers glutathione peroxidase-1 (GLPX1), superoxide dismutase (SOD), and malondialdehyde (MDA) in the kidney tissues, were assessed.
Results: Compared with the control group, and as expected, the GM-injected rats showed significant biochemical and histological changes denoting renal damage.
Compared with GM-injected rats, the concurrent administration of TQ with GM significantly reduced the levels of serum creatinine, serum urea, and tissue MDA and significantly increased the levels of GLPX1 and SOD.
Concurrent metformin administration with GM significantly increased the levels of both GLPX1 and SOD and significantly decreased the levels of tissue MDA but had no significant effect on serum creatinine and urea levels.
Compared with GM-injected rats, the addition of either TQ or MF resulted in a reduction in endothelial proliferation and mesangial hypercellularity.
Conclusions: Both TQ and MF effectively alleviated the oxidative stress in GM-induced nephrotoxicity in rats, with TQ but not MF producing a complete reno-protective effect.
Further studies for evaluation of different reno-protective mechanisms of TQ should be conducted.
Related Results
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract 2765: Metformin represses cancer cells via alternate pathways in N-Cadherin wild-type and N-Cadherin-deficient cells
Abstract
BACKGROUND
Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer agent...
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract PO1-05-11: Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study
Abstract
Background: Metformin, an oral biguanide used for the treatment of type-2 diabetes mellitus (DM), has been shown in a considerable number of studies to have...
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract
Introduction and Objective. Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer age...
Morning exercise and pre-breakfast metformin interact to reduce glycaemia in people with Type 2 Diabetes: a randomized crossover trial
Morning exercise and pre-breakfast metformin interact to reduce glycaemia in people with Type 2 Diabetes: a randomized crossover trial
Abstract
Exercise is recommended in the treatment of Type 2 Diabetes and can improve insulin sensitivity [1]. However, previous evidence suggests that exercise at d...
Clinical Pharmacology of Gentamicin
Clinical Pharmacology of Gentamicin
Gentamicin is an important agent for the treatment of many serious gram-negative bacillary infections. Gentamicin is the aminoglycoside of first-choice because the reliable activit...
Renal function and oxidative stress following gentamicin induced renal injury in rats treated with erythropoietin, iron and vitamine E
Renal function and oxidative stress following gentamicin induced renal injury in rats treated with erythropoietin, iron and vitamine E
Effects of erythropoietin, iron, and vitamin E on renal function and oxidative stress induced by gentamicin in rats were investigated. Rats were divided into 5 groups; group 1 (con...
Reduced Enzymatic Antioxidant Defense Mechanism in Kidney Tissues from Gentamicin-Treated Guinea Pigs: Effects of Vitamins E and C
Reduced Enzymatic Antioxidant Defense Mechanism in Kidney Tissues from Gentamicin-Treated Guinea Pigs: Effects of Vitamins E and C
In this study, the activities of major enzymes participating in free radical metabolism (xanthine oxidase, XO; CuZn and Mn superoxide dismutases, SOD; glutathione peroxidase, GSH-P...
Vitamin B12 Status in Metformin Treated Diabetics: Cross Sectional Study
Vitamin B12 Status in Metformin Treated Diabetics: Cross Sectional Study
Background: Metformin is the most commonly used drug for patients with type 2 diabetes mellitus (T2DM) patients. Metformin related vitamin B12 deficiency can cause anemia. Accordin...

